Donepezil slows decline in ADL


REPORT FROM THE 2009 AAN ANNUAL MEETING – A pooled analysis (n=2,177) of six randomized double-blind trials of donepezil in Alzheimer’s disease has found that treatment is associated with a reduced decline in activities of daily living (ADL) (Gauthier et al. AAN 2009; abstract P06.079).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page